Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 17, 2013, Pages 5107-5117

  Bruder, Marjorie ^a   Vendramini Costa, Débora Barbosa ^a   De Carvalho, João Ernesto ^a   Pilli, Ronaldo Aloise ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antiproliferative activity 2,5 Dihydrofuran 2 ones; Cancer cells; Goniothalamin

Indexed keywords

3 METHYL 1 PHENYLHEXA 1,5 DIEN 3 YL PROP 2 ENOATE; 4 [2 [(TERT BUTYLDIMETHYLSILYL)OXY]PHENYL]BUT 3 EN 2 ONE; 4 [3 [(TERT BUTYLDIMETHYLSILYL)OXY]PHENYL]BUT 3 EN 2 ONE; 4 [4 [(TERT BUTYLDIMETHYLSILYL)OXY] 3,5 DIMETHOXYPHENYL]BUT 3 EN 2 ONE; 4 [4 [(TERT BUTYLDIMETHYLSILYL)OXY]PHENYL]BUT 3 EN 2 ONE; 5 [2 (2 HYDROXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 [2 (2 METHOXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 [2 (3 HYDROXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 [2 (3 METHOXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 [2 (4 HYDROXY 3,5 DIMETHOXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 [2 (4 HYDROXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 [2 (4 METHOXYPHENYL)ETHENYL] 5 METHYL 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (2,3,4 TRIMETHOXYPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (2,4 DIMETHOXYPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (2,4,5 TRIMETHOXYPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (3,4 DIMETHOXYPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (3,4,5 TRIMETHOXYPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (3,4,6 TRIMETHOXYPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 (4 TRIFLUOROMETHYLPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [2 PHENYLETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [4 (2 TRIFLUOROMETHYLPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 [4 (4 FLUOROPHENYL)ETHENYL] 2,5 DIHYDROFURAN 2 ONE; 5 METHYL 5 STYRYL 2,5 DIHYDROFURAN 2 ONE; ANTINEOPLASTIC AGENT; DOXORUBICIN; ETHYL 4 HYDROXY 4 METHYL 6 PHENYLHEX 5 EN 2 YNOATE; FURAN DERIVATIVE; GONIOTHALAMIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN 786 0; CELL STRAIN HT 29; CELL STRAIN K 562; CELL STRAIN MCF 7; CELL STRAIN NCI ADR; CELL STRAIN PC 3; CELL STRAIN U251; CELL STRAIN UACC 62; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROPHILICITY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; LEUKEMIA; MELANOMA; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PROSTATE CANCER; REDUCTION; STRUCTURE ACTIVITY RELATION;

2,5-DIHYDROFURAN-2-ONES; ANTIPROLIFERATIVE ACTIVITY; CANCER CELLS; GONIOTHALAMIN;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HT29 CELLS; HUMANS; K562 CELLS; MCF-7 CELLS; PYRONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881373037     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.06.044     Document Type: Article

References (60)

1. A. Ali, M.M. Mackeen, M. Hamid, Q.B. Aun, Y. Zauyah, H.L.P. Azimahtol, and K. Kawazu Planta Med. 63 1997 81
2. A. de Fátima, L.K. Kohn, M.A. Antonio, J.E. de Carvalho, and R.A. Pilli Bioorg. Med. Chem. 13 2005 2927
3. A. de Fátima, L.K. Kohn, J.E. de Carvalho, and R.A. Pilli Bioorg. Med. Chem. 14 2006 622
4. For antiproliferative activities against lung and liver cell lines, see: C.-C. Chiu, P.-L. Liu, K.-J. Huang, H.-M. Wang, K.-F. Chang, C.-K. Chou, F.-R. Chang, I.-W. Chong, K. Fang, J.-S. Chen, H.-W. Chang, and Y.-C. Wu J. Agric. Food. Chem. 59 2011 4288
5. M. Al-Qubaisi, R. Rozita, S.-K. Yeap, A.-R. Omar, A.-M. Ali, and N.B. Alitheen Molecules 16 2011 2944
6. M.R. Khan, K. Komine, and A.D. Omoloso Pharm. Biol. 37 1999 340
7. M.A. Mosaddik, and M.E. Haque Phytother. Res. 17 2003 1157
8. C.V.B. Martins, M.A. de Resende, D.L. da Silva, T.F.F. Magalhães, L.V. Modolo, R.A. Pilli, and A. de Fátima J. Appl. Microbiol. 107 2009 1279
9. C.V.B. Martins, M.A. de Resende, T.F.F. Magalhães, B.H.S. Santiago, G.A. Watanabe, A.L.T.G. Ruiz, J.E. de Carvalho, R.A. Pilli, and A. de Fátima Lett. Drug Des. Discov. 5 2008 74
10. K.E. Kabir, A.R. Khan, and M.A. Mosaddik JEN 2003 112
11. S. Senthil-Nathan, M. Choi, C. Paik, and K. Kalaivani Chemosphere 72 2008 1393
12. N.F. Rajab, Z.A. Hamid, H. Hassan, A.M. Ali, L.B. Din, and S.H. Inayat-Hussain Environ. Mutagen. Res. 27 2005 161
13. Y. Lan, F. Chang, J. Yu, Y. Yang, Y. Chang, S. Lee, and Y. Wu J. Nat. Prod. 66 2003 487
14. A. de Fátima, C. Marquissolo, S. Albuquerque, A.A. Carraro-Abrahão, and R.A. Pilli Eur. J. Med. Chem. 41 2006 1210
15. S. Inayata-Hussain, B.O. Annuar, L.B. Din, A.M. Ali, and D. Ross Toxicol. In Vitro 17 2003 433
16. S.H. Inayat-Hussain, A.B. Osman, L.B. Din, A.M. Ali, R.T. Snowden, M. MacFarlane, and K. Cain FEBS Lett. 456 1999 379
17. A.H.L. Pihie, J. Stanlsas, and L. Bin Din Anticancer Res. 18 1998 1739
18. A. de Fátima, W.F. Zambuzzi, L.V. Modolo, C.A.B. Tarsitano, F.R. Gadelha, S. Hylsop, J.E. de Carvalho, I. Salgado, C.V. Ferreira, and R.A. Pilli Chem. Biol. Interact. 176 2008 143
19. J.-Y. Wach, S. Güttinger, U. Kutay, and K. Gademann Bioorg. Med. Chem. Lett. 20 2010 2843
20. R.A. Pilli, J.E. de Carvalho, D. Vendramini-Costa, I.D.B. de Castro, A.L.T. Ruiz, and C. Marquissolo Bioorg. Med. Chem. 18 2010 6742
21. A. de Fátima, L.V. Modolo, L.S. Conegero, R.A. Pilli, C.V. Ferreira, L.K. Kohn, and J.E. de Carvalho Curr. Med. Chem. 13 2006 3371
22. L. Bialy, and H. Waldmann Chem. Commun. 2003 1872
23. S.B. Buck, C. Hardouin, S. Ichikawa, D.R. Soenen, C.-M. Gauss, I. Hwang, M.R. Swingle, K.M. Bonness, R.E. Honkanen, and D.L. Boger J. Am. Chem. Soc. 125 2003 15694
24. F.S. Zhou, W.D. Tang, Q. Mu, G.X. Yang, Y. Wang, G.L. Liang, and L.G. Lou Chem. Pharm. Bull. 11 2005 1387
25. P. Kasaplar, O. YIlmazer, and A. ÇaǧIr Bioorg. Med. Chem. 17 2009 311
26. R.C. Barcelos, J.C. Pastre, V. Caixeta, D.B. Vendramini-Costa, J.E. de Carvalho, and R.A. Pilli Bioorg. Med. Chem. 20 11 2012 3635
27. K.G. Pinney, C. Jelinek, K. Edvardsen, D.J. Chaplin, and G.R. Pettit G.M. Cragg, D.G.I. Kingston, D.J. Newman, Anticancer Agents from Natural Products 2005 CRC Press Boca Raton, FL 23 46
28. D.G.I. Kingston J. Nat. Prod. 72 2009 507
29. S. Sale, R.D. Verschoyle, D. Boocock, D.J.L. Jones, N. Wilsher, K.C. Ruparelia, G.A. Potter, P.B. Farmer, W.P. Steward, and A.J. Gescher Br. J. Cancer 90 2004 736
30. S. Sale, R.G. Tunstall, K.C. Ruparelia, G.A. Potter, W.P. Steward, and A.J. Gescher Int. J. Cancer 115 2005 194
31. Z. Ma, O. Molavi, A. Haddadi, R. Lai, R.A. Gossage, and A. Lavasanifar Cancer Chemother. Pharmacol. 63 2008 27
32. V.P. Androutsopoulos, K.C. Ruparelia, A. Papakyriakou, H. Filippakis, A.M. Tsatsakis, and D.A. Spandidos Eur. J. Med. Chem. 46 2011 2586
33. S. Zhang, Y. Zhang, Y. Ji, H. Li, and W. Wang Chem. Commun. 2009 4886
34. L. Hao, L. Yafei, Z. Shilei, Y. ChenGuang, and W. Wei Sci. China Chem. 53 2010 135
35. L. Dumitrescu, D.T.M. Huong, N.V. Hung, and B. Crousse Eur. J. Med. Chem. 45 2010 3213
36. S.J. Stachel, C.B. Lee, M. Spassova, M.D. Chappell, W.G. Bornmann, S.J. Danishefsky, T.-C. Chou, and Y. Guan J. Org. Chem. 66 2001 4369
37. J. Mulzer, K.-H. Altmann, G. Höfle, R. Müller, and K. Prantz C.R. Chim. 11 2008 1336
38. http://www.cancer.gov/cancertopics/druginfo/fda-ixabepilone, accessed on January 13, 2012.
39. W. Wilk, H. Waldmann, and M. Kaiser Bioorg. Med. Chem. 17 2009 2304
40. K.C. Chang, C.-Y. Duh, I.-S. Chen, and I.-L. Tsai Planta Med. 69 2003 667
41. N. Hoshi, H. Hagiwara, and H. Uda Chem. Lett. 1979 1295
42. While this work was under preparation, Mohideen et al. described the synthesis and biological activity against Jurkat cells of 3,4-dihydrofuran-2- ones: M. Mohideen, S. Zulkepli, N.-S. Nik-Salleh, M. Zulkefeli, J.-F.F.A. Weber, and A.F.M.M. Rahman Arch. Pharm. Res. 2013 10.1007/s12272-013-0099-1 (published online March 31, 2013)
43. M.-A. Virolleaud, C. Bressy, and O. Piva Tetrahedron Lett. 44 2003 8081
44. M.-A. Virolleaud, and O. Piva Synlett 2004 2087
45. J. Song, and R. Hollingsworth I Tetrahedron: Asymmetry 12 2001 387
46. S. Takamatsu, M.-C. Rho, M. Hayashi, K. Komiyama, H. Tanaka, and S. Omura J. Antibiot. 46 1993 1526
47. T. Takahashi, H. Watanabe, and T. Kitahara Tetrahedron Lett. 44 2003 9219
48. S.P. Saberi, and S.E. Thomas J. Chem. Soc., Perkin Trans. 1 1992 259
49. K. Yoshida, Y. Shishikura, H. Takahashi, and T. Imamoto Org. Lett. 10 2008 2777
50. P. Srihari, B. Kumaraswamy, G.M. Rao, and J.S. Yadav Tetrahedron: Asymmetry 21 2010 106
51. V. Shekhar, D.K. Reddy, V. Suresh, D.C. Babu, and Y. Venkateswarlu Tetrahedron Lett. 51 2010 946
52. P. Soucy, A. L'Heureux, A. Toró, and P. Deslongchamps J. Org. Chem. 68 2003 9983
53. K.R. Campos, D. Cai, M. Journet, J.J. Kowal, R.L. Larsen, and P.J. Reider J. Org. Chem. 66 2001 3634
54. For a review, see: C.H. Heathcock B.M. Trost, I. Fleming, C.H. Heathcock, Comprehensive Organic Synthesis Vol. 2 1991 Pergamon Elsevier Oxford 133 180
55. K. Zumbansen, A. Döhring, and B. List Adv. Synth. Catal. 352 2010 1135
56. X. Moreau, B. Bazán-Tejeda, and J.-M. Campagne J. Am. Chem. Soc. 127 2005 7288
57. F. Arcamone Cancer Res. 45 1985 5995
58. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, and M. Boyd J. Natl. Cancer Inst. 83 1991 757
59. R. Shoemaker Nat. Rev. Cancer. 6 2006 813
60. W.K. Hagmann J. Med. Chem. 51 15 2008 4359